The rising interest in successful weight management has resulted in considerable exploration into groundbreaking treatments. Lately , Retatrutide, a combined -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist , has shown encouraging results in clinical trials, implying potential for consi